Abstract 84P
Background
Tumor-specific neoantigens arising from non-synonymous mutations have become increasingly attractive targets for immunotherapies. The accurate identification and prioritization of neoantigens is crucial to design personalized therapies for each cancer patient. Putative immunogenic neoantigens are currently selected by using several peptide-HLA-I binding predictors. While HLA-I binding affinity is essential to tumor cell presentation of neoantigens, it is insufficient to determine neoantigen immunogenicity. As such, the vast majority of predicted tumor neoantigens (98%) are not immunogenic and ineffective in activating antitumor responses. To address this challenge, we propose integrating T-cell receptor (TCR) repertoire profiles of tumor infiltrating lymphocytes (TILs), a key determinant of immunogenicity, in the current neoantigen prediction workflow.
Methods
We sequenced the CDR3 regions of TCR beta chain (TCRB) repertoire in 27 colorectal cancer (CRC) patients and predicted neopeptide-TCR binding by using our previously published predictor, epiTCR and another existing tool pMTNet. We constructed a machine learning model which considers both peptide-HLA-I and peptide-TCR binding features to prioritize high quality immunogenic neoantigen candidates. We further performed ELISpot assay on autologous PBMCs from four CRC patients to experimentally validate the effectiveness of our model. Finally, we selected the highest immunogenic candidate to perform 10X single-cell sequencing to identify the potential neoantigen-specific TCRs for cell-based vaccine development.
Results
We showed that 5.5% of neopeptide candidates despite having weak HLA-I binding affinity are capable of binding to TCR at predicted rank < 2%. The integrated model achieved higher accuracy for ranking immunogenic neopeptides than the conventional NetMHCpan tool solely relying on peptide-HLA-I binding features.
Conclusions
Our study presents an efficient process to select and prioritize neoantigens exhibiting both HLA presentation and immunogenicity for personalized cancer immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract